Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2174/0929867327666200721161840 http://scihub22266oqcxt.onion/10.2174/0929867327666200721161840 32693756!7611096!32693756     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Med+Chem 2021 ; 28 (19): 3803-3824 Nephropedia Template TP {{tp|p=32693756|t=2021. Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19 |pdf=|usr=}}{{32693756}} gab.com Text Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19 JO: Curr Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=32693756 #FOAvip The novel coronavirus (SARS-CoV-2) pandemic has created a global public health emergency. The pandemic is causing substantial morbidity, mortality and significant economic loss. Currently, no approved treatments for COVID-19 are available, and it is likely to takes at least 12-18 months to develop a new vaccine. Therefore, there is an urgent need to find new therapeutics that can be progressed to clinical development as soon as possible. Repurposing regulatory agency-approved drugs and experimental drugs with known safety profiles can provide important repositories of compounds that can be fast-tracked to clinical development. Globally, over 500 clinical trials involving repurposed drugs have been registered, and over 150 have been initiated, including some backed by the World Health Organisation (WHO). This review is intended as a guide to research into small-molecule therapies to treat COVID-19; it discusses the SARS-CoV-2 infection cycle and identifies promising viral therapeutic targets, reports on a number of promising pre-approved small-molecule drugs with reference to over 150 clinical trials worldwide, and offers a perspective on the future of the field. Twit Text FOAVip Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19 ????Curr Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=32693756 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32693756 #FOAvip English Wikipedia <ref>{{Cite pmid|32693756}}</ref> Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19 #MMPMID32693756 Laws M; Surani YM; Hasan MM; Chen Y; Jin P; Al-Adhami T; Chowdhury M; Imran A; Psaltis I; Jamshidi S; Nahar KS; Rahman KM Curr Med Chem 2021[]; 28 (19): 3803-3824 PMID32693756show ga The novel coronavirus (SARS-CoV-2) pandemic has created a global public health emergency. The pandemic is causing substantial morbidity, mortality and significant economic loss. Currently, no approved treatments for COVID-19 are available, and it is likely to takes at least 12-18 months to develop a new vaccine. Therefore, there is an urgent need to find new therapeutics that can be progressed to clinical development as soon as possible. Repurposing regulatory agency-approved drugs and experimental drugs with known safety profiles can provide important repositories of compounds that can be fast-tracked to clinical development. Globally, over 500 clinical trials involving repurposed drugs have been registered, and over 150 have been initiated, including some backed by the World Health Organisation (WHO). This review is intended as a guide to research into small-molecule therapies to treat COVID-19; it discusses the SARS-CoV-2 infection cycle and identifies promising viral therapeutic targets, reports on a number of promising pre-approved small-molecule drugs with reference to over 150 clinical trials worldwide, and offers a perspective on the future of the field. |*COVID-19[MESH] |Antiviral Agents/therapeutic use[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Pandemics[MESH]Current Trends and Future Approaches in Small-Molecule Therapeutics fo(epmc).pdf DeepDyve Pubget Overpricing